• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LENSAR Inc. filed SEC Form 8-K: Leadership Update

    4/15/26 4:30:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email
    8-K
    false000132035000013203502026-04-102026-04-10

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 10, 2026

     

     

    LENSAR, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39473

    32-0125724

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2800 Discovery Drive

     

    Orlando, Florida

     

    32826

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 888 536-7271

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, par value $0.01 per share

     

    LNSR

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On April 10, 2026, Thomas R. Staab, II, Chief Financial Officer of LENSAR, Inc. (the “Company”), notified the Company of his intention to resign from this position, effective May 8, 2026 (the “Transition Date”), to pursue other professional opportunities. Mr. Staab will continue serving as the Company’s principal financial officer through the Transition Date. Mr. Staab’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company has commenced a search for a new Chief Financial Officer.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    LENSAR, Inc.

     

     

     

     

    Date:

    April 15, 2026

    By:

    /s/ Nicholas T. Curtis

     

     

     

    Nicholas T. Curtis
    Chief Executive Officer

     


    Get the next $LNSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    4/1/2026$10.00Hold → Buy
    Lake Street
    3/18/2026$10.00Neutral → Buy
    BTIG Research
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    SEC Filings

    View All

    SEC Form S-8 filed by LENSAR Inc.

    S-8 - LENSAR, Inc. (0001320350) (Filer)

    6/2/26 4:33:20 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Leadership Update, Shareholder Director Nominations, Other Events

    8-K - LENSAR, Inc. (0001320350) (Filer)

    5/29/26 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by LENSAR Inc.

    SCHEDULE 13G/A - LENSAR, Inc. (0001320350) (Subject)

    5/14/26 4:58:58 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    LENSAR upgraded by Lake Street with a new price target

    Lake Street upgraded LENSAR from Hold to Buy and set a new price target of $10.00

    4/1/26 9:08:15 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR upgraded by BTIG Research with a new price target

    BTIG Research upgraded LENSAR from Neutral to Buy and set a new price target of $10.00

    3/18/26 8:19:03 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    BTIG initiated coverage on LENSAR with a new price target

    BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

    11/22/21 6:09:40 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENSAR® Reports First Quarter 2026 Results and Provides Business Update

    7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs to 440 Systems, Driven by 39% Growth in ALLY Placements ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2026 and provided an update on key operational initiatives. "Our first quarter total revenue and related system placement results decre

    5/8/26 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR® to Report First Quarter 2026 Results on May 8, 2026

    ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR's management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives. To participate by telephone, please use this registration link. All participants must use the link to complete the online registra

    4/30/26 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

    15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over December 31, 2024 Recurring revenue exceeded $46.3 million for the full year; increased 15% over 2024 ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on key operational initiatives. "Wh

    3/31/26 6:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,739 shares, decreasing direct ownership by 0.77% to 354,330 units (SEC Form 4) (tax liability)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/8/26 5:00:23 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4) (for withholding tax)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/8/26 5:00:25 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,350 shares, decreasing direct ownership by 0.77% to 174,609 units (SEC Form 4) (tax withholding)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/8/26 5:00:20 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR® Reports First Quarter 2026 Results and Provides Business Update

    7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs to 440 Systems, Driven by 39% Growth in ALLY Placements ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2026 and provided an update on key operational initiatives. "Our first quarter total revenue and related system placement results decre

    5/8/26 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR® to Report First Quarter 2026 Results on May 8, 2026

    ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026. LENSAR's management will host a conference call and webcast at 8:30 am ET on Friday, May 8, 2026 to discuss the results, recent corporate and operational highlights and provide an update on key strategic initiatives. To participate by telephone, please use this registration link. All participants must use the link to complete the online registra

    4/30/26 7:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

    15 ALLY Robotic Cataract Laser Systems® ("ALLY Systems") placed in 4Q 2025; Backlog of 13 ALLY Systems pending installation as of December 31, 2025 ALLY installed base grew 48%, total laser installed base grew 13% over December 31, 2024 Recurring revenue exceeded $46.3 million for the full year; increased 15% over 2024 ORLANDO, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on key operational initiatives. "Wh

    3/31/26 6:00:00 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care